TREMFYA® (guselkumab) receives positive CHMP opinion for treatment of adult patients with moderately to severely active ulcerative colitis


Recommendation based on the findings from the Phase 3 QUASAR programme in ulcerative colitis1

Link:
TREMFYA® (guselkumab) receives positive CHMP opinion for treatment of adult patients with moderately to severely active ulcerative colitis

Related Posts